Villere ST Denis J & Co. LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 83,598 shares of the medical technology company’s stock after selling 1,820 shares during the period. Stryker accounts for approximately 3.2% of Villere ST Denis J & Co. LLC’s investment portfolio, making the stock its 9th biggest position. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $33,074,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. PDS Planning Inc raised its position in Stryker by 42.0% during the 2nd quarter. PDS Planning Inc now owns 2,516 shares of the medical technology company’s stock worth $996,000 after purchasing an additional 744 shares during the last quarter. Cascade Investment Group Inc. raised its position in Stryker by 6.3% during the 2nd quarter. Cascade Investment Group Inc. now owns 588 shares of the medical technology company’s stock worth $233,000 after purchasing an additional 35 shares during the last quarter. L. Roy Papp & Associates LLP raised its position in Stryker by 1.2% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 62,910 shares of the medical technology company’s stock worth $24,889,000 after purchasing an additional 726 shares during the last quarter. Baskin Financial Services Inc. raised its position in Stryker by 0.6% during the 2nd quarter. Baskin Financial Services Inc. now owns 112,795 shares of the medical technology company’s stock worth $44,625,000 after purchasing an additional 674 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI raised its position in Stryker by 0.3% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 60,899 shares of the medical technology company’s stock worth $24,093,000 after purchasing an additional 160 shares during the last quarter. 77.09% of the stock is owned by institutional investors.
Insider Transactions at Stryker
In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Check Out Our Latest Report on SYK
Stryker Price Performance
SYK stock opened at $364.77 on Friday. The stock has a market capitalization of $139.46 billion, a PE ratio of 48.31, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94. The company’s 50-day moving average is $380.25 and its 200-day moving average is $378.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
- Five stocks we like better than Stryker
- Stock Market Upgrades: What Are They?
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- Top Stocks Investing in 5G Technology
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- Short Selling – The Pros and Cons
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.